Investors Trading Alert: Ionis Pharmaceuticals, Inc.’s (IONS)


Ionis Pharmaceuticals, Inc.’s (IONS) witnessed a gain of 2.48% in recent trading period with closing price of $ 42.91. The company’s last traded volume of 0.98 million shares was more it’s an average volume of 1.68 million shares.

In the trailing 12 months period, return on assets ratio of the Company was -10.10% and return on equity ratio was -68.10% while its return on investment ratio was -7.70%. The stock as of last trading session moved 119.01% up from its 52 week low and was -24.72% behind its 52 week high.

The stock’s price switched up 8.51% 20-Days Simple Moving Average, dropped -0.53% from 50-Days Simple Moving Average and rose 10.97% from 200 Days Simple Moving Average. The company has price to cash ratio of 7.96.

In the profitability analysis, net profit margin of the firm was recorded at -25.00% and operating profit margin was calculated at -14.50% while gross profit margin was measured as 16.60%. Beta factor, which measures the riskiness of the security, was registered at 2.58.

Looking about the past performance history, the company jumped 9.05% in past week and climbed 12.21% in one month. During the past three month period the stock dropped -8.12% and increased 49.93% in past six month. During the twelve month it lost -1.63% and year to date performance of -10.29%.

EPS growth for this year is 2.90% and EPS growth for next year is expected to reach at 54.00%. EPS growth in past five years was 3.40% while EPS growth in next five years is projected to arrive at 41.00%. Sales growth past 5 years was measured at 28.50%.

In the liquidity ratio analysis; quick ratio for most recent quarter was 5.90 while current ratio for time period was 6.00. In most recent quarter, LT Debt/Equity ratio was listed at 5.90 and Total Debt/Equity ratio was noted at 5.91.

The Company has 123.88 million shares outstanding and 122.92 million shares were floated in market. The short ratio in the company’s stock is documented at 7.10 and the short float is around of 9.72%. The average true range of the stock is observed at 1.62 and the relative strength index of the stock is recorded at 58.03.

Analyst recommendation for this stock stands at 2.80. The volatility in the previous week has experienced by 4.30% and observed of 3.93% in the previous month.88.90% ownership is held by institutional investors while insiders hold ownership of 0.20%.

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. It markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. The company’s drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. It is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. In addition, the company is developing products, which are Phase II clinical trials include IONIS-DMPK-2.5Rx for myotonic dystrophy type 1; IONIS-HTTR for huntington’s disease; ATL1103 for acromegaly; IONIS-FXIRx (BAY 2306001) for clotting disorders; IONIS-APO(a)-LRx for high Lp; IONIS-ANGPTL3-LRx for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5Rx (AZD9150) for cancers; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; and RG-101 for hepatitis C virus infection, as well as products for the treatment of diabetes and obesity. Further, its products in Phase I clinical include IONIS-GCCRRx for cushing’s syndrome; IONIS-PKKRx for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5Rx (AZD5312) for prostate cancer; IONIS-HBVRx for hepatitis B virus infection; IONIS-GSK4-LRx for ocular disease; and IONIS-DGAT2Rx for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Previous articleTraders Focused Stock: Acacia Communications’s (ACIA)
Next articleInvestors Spotlight: Achillion Pharmaceuticals, Inc.’s (ACHN)
Martin Almanza covers the Business news across the all us market sectors for He has over 5 years experience writing financial and business news. He is a graduate of the University of Florida graduating with an MBA. He focuses on adding value to investors' portfolios via thoroughly checked proprietary information and data sources. He has a very strong interest in stock trading, and other various investments. He currently lives in Fort Myers, FL with his wife Heidi.